Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.77 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8199849 | 0.98 | ALDH1A1 (0.74) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL2015532 | 0.98 | ALDH1A1 (0.74) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL7961779 | 0.95 | ALDH1A1 (0.70) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL15854998 | 0.94 | ALDH1A1 (0.68) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL3905679 | 0.90 | CA12 (0.72) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL3898192 | 0.89 | CA12 (0.70) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL472226 | 0.89 | CA12 (0.70) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL7095728 | 0.89 | CA12 (0.66) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL7203889 | 0.89 | CA12 (0.70) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL6130663 | 0.88 | ALDH1A1 (0.60) | ALDH1A1CA12CA2CA9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190276416-A1 | METHOD FOR PREPARING NOTA DERIVATIVE | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. (TW) | 2019-09-12 | — | — | US | claimed |
| US-20250057990-A1 | TISSUE-SPECIFIC MANGANESE BASED MRI CONTRAST AGENTS | UNIV CASE WESTERN RESERVE (US) | 2025-02-20 | — | — | US | disclosed |
| US-20230288610-A1 | WAVELENGTH SELECTIVE ABSORPTION FILTER AND DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230288610-A1 | WAVELENGTH SELECTIVE ABSORPTION FILTER AND DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| WO-2023122564-A2 | TISSUE-SPECIFIC MANGANESE BASED MRI CONTRAST AGENTS | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20190276416-A1 | METHOD FOR PREPARING NOTA DERIVATIVE | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. (TW) | 2019-09-12 | — | — | US | disclosed |
| US-9988388-B2 | Synthesis of imidazo[1,2-a]pyrazin-4-ium salts for the synthesis of 1,4,7-triazacyclononane (tacn) and N- and/or C- functionalized derivatives thereof | UNIVERSITE DE BOURGOGNE (FR) | 2018-06-05 | — | — | US | disclosed |
| US-9981967-B2 | Synthesis of imidazo[1,2-a]pyrazin-4-ium salts for the synthesis of 1,4,7-triazacyclononane (tacn) and N- and/or C-functionalized derivatives thereof | UNIVERSITE DE BOURGOGNE (FR) | 2018-05-29 | — | — | US | disclosed |
| US-9726932-B2 | Optical film, optical compensation film, polarizing plate and liquid crystal display | FUJIFILM CORPORATION (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9726932-B2 | Optical film, optical compensation film, polarizing plate and liquid crystal display | FUJIFILM CORPORATION (JP) | 2017-08-08 | — | — | US | disclosed |
| US-5386028-A | Process for the production of N-β-hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecane and N-β-hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecane derivatives and their metal complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-01-31 | — | — | US | disclosed |
| EP-0598753-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0545511-A2 | Process for the preparation of mono-N-substituted tetraazamacrocycles | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-06-09 | — | — | EP | disclosed |
| WO-1993002090-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1993-02-04 | — | — | WO | disclosed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | disclosed |
| EP-0352218-A2 | Macrocyclic polyaza compounds containing rings with 5 or 6 members, methods for their preparation and pharmaceutical compositions containing same | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-01-24 | — | — | EP | disclosed |
| US-4639365-A | Gadolinium chelates as NMR contrast agents | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0198051-A1 | GADOLINIUM CHELATES AS NMR CONTRAST AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1986-10-22 | — | — | EP | disclosed |
| WO-1986002352-A1 | GADOLINIUM CHELATES AS NMR CONTRAST AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1986-04-24 | — | — | WO | disclosed |
| US-4001212-A | EXTRACT METAL IONS FROM SOLUTION AND COMPLEX | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057990-A1 | TISSUE-SPECIFIC MANGANESE BASED MRI CONTRAST AGENTS | TFRC, MTPN, MYADM | ALDH1A1 4728/4885CA12 493/4885CA2 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.